The historic rise of Viagra has long been a benchmark of pharmaceutical success, however its future within the broader sector now presents questions about long-term returns . Alternative versions are eroding exclusivity , prompting concerns that betting on companies heavily reliant to Viagra's previous standing could be a problematic strategy, espe